by Suzanne Vyse on April 28, 2026
by John LaRosa on March 19, 2026
The value of the total market is estimated to have grown to a historic peak of $135 billion in 2025, boosted by soaring sales of the popular prescription GLP-1 weight loss drugs. This is a paradigm shift to medical programs, and a major challenge for competing commercial weight loss companies.
by John LaRosa on January 13, 2026
Demand for mental health services soared with the pandemic and 61 million Americans (more than one in five adults) now have some form of mental illness, with prevalence among adolescents rising sharply.
by John LaRosa on June 17, 2025
Meditation has become more mainstream in America, with interest soaring during the pandemic for apps like Calm and Headspace.
by BIS Research on June 10, 2025
Precision medicine is reshaping healthcare by tailoring treatments to a person’s genetic makeup, lifestyle, and environment.
by BIS Research on April 22, 2025
Something big is happening in American hospitals—and it’s not another shiny new device or a blockbuster drug. It’s a quiet, behind-the-scenes transformation driven by smart software that’s getting better at understanding how doctors think, how patients behave, and how diseases unfold.
by John LaRosa on March 25, 2025
The $38 billion U.S. commercial weight loss market is 15% larger than in 2020, but has had to pivot to adjust to huge competition from the popular GLP-1 drugs.
by John LaRosa on March 3, 2025
At no other time in the U.S. weight loss market history has one product so dominated the market as have the new GLP-1 weight loss drugs. American dieters have flocked to them, shunning commercial weight loss programs such as Weight Watchers, Medifast, as well as retail and MLM meal replacements.
by John LaRosa on January 13, 2025
Outpatient physical therapy is in demand, as the U.S. population ages. A stable reimbursement environment, private equity investment, and the popularity of PT as an alternative to opioids for pain management all contribute to a positive outlook through 2030.
by John LaRosa on September 9, 2024
An estimated 70 million Americans have insomnia, and 39 million suffer from obstructive sleep apnea (OSA), mostly undiagnosed. As obesity rates remain high, this problem is not likely to dissipate any time soon. Therefore, there is ample room for future growth of CPAP devices and sleep studies, performed at home or in specialized clinics.
Our goal is to help you better understand your customer, market, and competition in order to help drive your business growth.
MarketResearch.com
6116 Executive Blvd
Suite 550
Rockville, MD 20852
800.298.5699 (U.S.)
+1.240.747.3093 (International)
customerservice@marketresearch.com